BBR Partners LLC Grows Stock Position in Harrow, Inc. (NASDAQ:HROW)

BBR Partners LLC increased its holdings in Harrow, Inc. (NASDAQ:HROW) by 181.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,000 shares of the company’s stock after buying an additional 40,000 shares during the quarter. BBR Partners LLC owned 0.17% of Harrow worth $2,788,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in HROW. Vanguard Group Inc. raised its holdings in Harrow by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock worth $24,208,000 after purchasing an additional 21,253 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Harrow by 6.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock worth $221,000 after acquiring an additional 1,033 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in Harrow in the 1st quarter worth approximately $185,000. Opaleye Management Inc. raised its stake in Harrow by 2.6% during the 1st quarter. Opaleye Management Inc. now owns 3,920,600 shares of the company’s stock worth $51,870,000 after acquiring an additional 100,600 shares during the period. Finally, Private Capital Management LLC lifted its holdings in Harrow by 7.8% during the first quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock valued at $39,854,000 after purchasing an additional 217,896 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors.

Harrow Stock Up 0.5 %

Shares of HROW stock opened at $42.47 on Thursday. The company’s fifty day simple moving average is $47.76 and its two-hundred day simple moving average is $34.17. Harrow, Inc. has a 52 week low of $8.72 and a 52 week high of $59.23. The stock has a market cap of $1.51 billion, a P/E ratio of -45.18 and a beta of 0.76. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Lake Street Capital lifted their target price on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Craig Hallum boosted their price objective on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley reiterated a “buy” rating and set a $50.00 target price on shares of Harrow in a research report on Thursday, August 29th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.